Compare Mesoblast Limited (MESO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Verisign, Inc. — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Verisign, Inc. trades at $304.06 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 15.4× Mesoblast Limited's market cap, and Verisign, Inc. pays a 1.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Verisign, Inc. for 123 Days on average.
| MESO | VRSN | |
|---|---|---|
Market Cap | $1.75B | $26.92B |
Volume | 239,027 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $20.96 | $310.00 |
52-Week Low | $13.19 | $211.49 |
Typical Hold Time | 15 Days | 123 Days |
Enterprise Value | $1.83B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
VeriSign (VRSN) trades at $303.74, up 3.24% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 49.77% net income margin and consistent revenue growth, reaching $1.66B in 2025. Recent news includes an upcoming Q3 2026 earnings call and insider selling by the CEO, while institutional buying from firms like BlackRock signals confidence. A class-action antitrust lawsuit filed in September 2026 poses a regulatory risk.
The investment outlook is positive, driven by analyst consensus favoring a buy rating with a $348 price target, implying 15% upside. Key opportunities include AI-driven domain growth and a pending .com price increase. Risks involve the antitrust litigation, competitive pressures, and reliance on domain registry revenues. Earnings momentum is mixed, with Q2 2026 missing estimates but Q1 beating expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
